Method for detecting fluorescence and ablating cancer cells of a target surgical area

Information

  • Patent Grant
  • 11439307
  • Patent Number
    11,439,307
  • Date Filed
    Tuesday, December 3, 2019
    5 years ago
  • Date Issued
    Tuesday, September 13, 2022
    2 years ago
Abstract
A fluorescence imaging device detects fluorescence in parts of the visible and invisible spectrum, and projects the fluorescence image directly on the human body, as well as on a monitor, with improved sensitivity, video frame rate and depth of focus, and enhanced capabilities of detecting distribution and properties of multiple fluorophores. Direct projection of three-dimensional visible representations of florescence on three-dimensional body areas advantageously permits viewing of it during surgical procedures, including during cancer removal, reconstructive surgery and wound care, etc. A NIR laser and a human visible laser (HVL) are aligned coaxially and scanned over the operating field of view. When the NIR laser passes over the area where the florescent dye is present, it energizes the dye which emits at a shifted NIR frequency detected by a photo diode. The HVL is turned on when emission is detected, providing visual indication of those positions.
Description
FIELD OF INVENTION

This invention is related to the field of fluorescent medical imaging.


BACKGROUND OF INVENTION

Fluorescence is a phenomenon of light emission by a substance that has previously absorbed light of a different wavelength. In most cases, the emitted light has a longer wavelength, and therefore lower energy, than the absorbed light. However, when the absorbed electromagnetic radiation is intense, it is possible for one atom or molecule to absorb two photons; this two-photon absorption can lead to emission of radiation having a shorter wavelength than the absorbed radiation. Fluorescent light can be easily separated from reflected excitation light, thus providing excellent selectivity in applications where fluorescent light may carry some useful information about the substances and structures which emitted it.


This property is particularly important in various medical imaging applications, where fluorescent light may be emitted by fluorescent dyes, also known as fluorophores with affinity to certain biological materials such as blood, or dyes conjugated to biological markers with specific affinity to certain tissues, proteins or DNA segments, and can be a reliable proxy for imaging internal body structures, such as blood vessels, lymph nodes, etc., as well as finding signs of disease, such as necrosis or cancer.


Usually, fluorescent biological markers are introduced externally, specifically with a purpose of binding to and imaging specific organs and tissues. In some cases, they are naturally-occurring, which is known as biological auto-fluorescence.


Most fluorescent substances, whether biological or not, have specific absorption and emission spectra, with peaks at certain wavelength. Sometimes, more than one peak may be present in either absorption or emission spectrum, or both. In any case, any fluorescent imaging system must provide excitation light at one wavelength and detect the emission light at different wavelength. Since the optical efficiency of fluorescence is usually quite low, emission light is usually much weaker than excitation light. Hence, optical filters which accept emission light and block excitation light are also usually present in a fluorescent imaging system.


Of particular interest are the fluorescent dyes which both absorb and emit light in the Near Infrared (NIR) part of the spectrum, approximately from 700 to 1000 nm wavelength. Within this band, human tissues are particularly transparent, so the fluorescent dyes may be seen at most depths and images may be of particular clarity.


Fluorescent medical imaging systems are known in prior art, including those designed for detection of NIR fluorescent dyes.


Usually, fluorescent images are combined with conventional, reflected-light images and presented to a medical practitioner on a common monitor, so the distribution of the fluorescent die can be visible in its surroundings. Since the NIR fluorescent image is outside of the human visible light range, it is usually mapped to a human visible color and displayed on a monitor superimposed on top of the captured color image of the biological object of interest. The system can display either still or moving images. A medical practitioner can use such a system to detect, for example, cancer cells during surgery, detect perfusion during reconstructive surgery, and detect the location of lymph nodes. During open surgery, wherein the surgeon is directly viewing the field of surgery, utilization of a monitor is disadvantageous in the surgeon must glance away from the surgical site to view the image of the fluorescence. Upon returning to view the surgical area, the surgeon must estimate the position of the florescence based upon his memory of the display on the monitor. Alternative, the surgeon can perform the required work while directly viewing the monitor as opposed to directly viewing the surgical area. This approach is disadvantaged in that it is cumbersome to operate without directly viewing the surgical site. Further, when viewing the monitor the surgeon losses all three dimensional information that is normally obtained when directly viewing the surgical area.


While being valuable surgical and diagnostic tools, known fluorescent cameras suffer from a number of limitations, mostly stemming from very low signal levels produced by fluorescent dyes. Those limitations are insufficient sensitivity, low video frame rates or long integration time necessary for taking a still image, as well as a limited depth of focus, especially if a large objective lens is used to alleviate sensitivity problems.


There are many known fluorescent dyes and or molecules that are used in the medical field, also referred to florescent probes or fluorescent markers, (see, Thermo Scientific Fluorescent Probes, available at: www.piercenet.com/browse.cfm?fldID=4DD9D52E-5056-8A76-4E6E-E217FAD0D86B, the disclosures of which are hereby incorporated by reference).


Furthermore, in the following article, near-infrared fluorescence nanoparticle-base probes for use in imaging of cancer are described and is hereby incorporated by reference: He, X., Wang, K. and Cheng, Z. (2010), “In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes.” WIREs Nanomed Nanobiotechnol, 2: 349-366. doi: 10.1002/wnan.85.


OBJECTS OF THE INVENTION

It is an object of this invention to visualize fluorescence which is invisible to the human eye, either because it is outside of visible wavelength range, or because it is too weak to be seen by a naked eye, by re-projection directly onto human tissue on a surgical or diagnostic site and thus free the medical practitioner from shifting his sight from patient to monitor and back


It is another object of this invention to alleviate the deficiencies of existing fluorescent cameras and increase the sensitivity, the video frame rates and the depth of focus.


It is yet another object of this invention to enable a fluorescent camera to detect the presence of multiple fluorophores with distinct spectra in human tissues and adequately convey the information about their presence and distribution to the medical practitioner.


It is yet another object of this invention to detect temporal changes in fluorophore distribution and convey this information to the medical practitioner.


It is yet another object of this invention to enable detection of fluorescence life time of a fluorophore, which might convey additional clinically-relevant information about fluorophore distribution and interaction with surrounding tissues. It may also help to distinguish between fluorophores with the same spectra but different life time.


It is also an object of this invention to extract information about the depth of the fluorophore deposit in the human body, thus enabling 3-dimensional fluorescence imaging.


And it is also an object of this invention to improve the performance of fluorescence imaging in endoscopic applications.


Further objects and advantages of the invention will become apparent from the following description and claims, and from the accompanying drawings.


SUMMARY OF THE INVENTION

In this application a fluorescence imaging device is described which is capable of detecting fluorescence in visible and invisible parts of the spectrum and projecting the fluorescence image directly on the human body, as well as on the monitor, with improved sensitivity, video frame rate and depth of focus and enhanced capabilities of detecting distribution and properties of multiple fluorophores.


Projecting the visible representation of the florescence directly on the human body has the significant advantage of allowing the surgeon to view the florescence directly on the patient while performing the surgery. Since the parts of the body being operated on are three dimensional, tire viewing by the surgeon of the projected visible image thereon is therefore inherently three dimensional, providing an advantage to the surgeon.


An illustrative example where the present invention would be useful is open surgery for cancer removal. It is known that injecting a patient with fluorescent dyes conjugated with specific biological markers will cause the dyes to accumulate in cancer cells. With the present invention, during open surgery the surgeon can simply aim the device at the surgical area and all of the cancer cells will appear to be visually glowing due to the selective projection of the visible laser on the surgical area. In this manner the surgeon can make certain to only remove the cancerous materials, and can insure that all the cancerous cells are appropriately removed.


A further illustrative field is the area of reconstructive surgery and wound care. In these cases insuring that there is appropriate blood flow into parts of the body is critical. In this instance, during the reconstructive surgery the fluorescent dyes can be injected into the patients' blood stream and the device used to show the blood flow to the newly constructed area. By projecting directly onto the reconstructed area an image of the blood flow, the surgeon can insure in real time that the flow is appropriate to provide appropriate healing.


In one embodiment, the system includes a NIR laser for energizing the florescent dye, for example Indocyanine green (ICG). Also included is a human visible laser (i.e., a laser emitting light at a wavelength that is visible to the human eye) for displaying the areas where the florescence is detected. Both the NIR and the visible laser are aligned coaxially and scanned over the operating field of view. When the NIR laser passes over the area where the florescent dye is present, the dye emits at a shifted NIR frequency which is detected by a photo diode. Based upon the position of the NIR laser when the emission is detected, the position of the florescent dye is identified. The human visible laser is then turned on at positions corresponding to the position of the florescent dye, thereby providing a visual indication of the position of the florescent dye.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body.



FIG. 2—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body and on a monitor.



FIG. 3—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body, overlap the fluorescent image on the visible image from a CCD camera and display the combined image on a monitor.



FIG. 4—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body using full RGB colors, overlap the fluorescent image on the visible image from a full-color laser scanning camera and display the combined image on a monitor.



FIG. 5—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body using full RGB colors, overlap the fluorescent image on the visible image from a full-color laser scanning camera and display the combined image on a monitor. This device has an additional ablation laser, capable of controlled delivery of laser light to select regions of the human body designated based on the acquired fluorescence image.



FIG. 6—this block diagram describes a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body, overlap the fluorescent image on the visible image from a CCD camera and display the combined image on a monitor. This device uses an imaging, rather than a laser scanning, projector, such as a Digital Light Processor (DLP) projector.



FIG. 7—this drawing shows a simplified layout of the device of FIG. 3.



FIG. 8—this drawing shows the difference between the imaging and non-imaging light collection and the advantage of the latter for a fluorescence imaging device.



FIG. 9—this drawing shows a simplified layout of an endoscopic fluorescence imaging device.



FIG. 10—these graphs show the difference between temporal responses of short and long fluorescent life fluorophores while excited by a laser scanning beam.



FIG. 11—this drawing shows a simplified optical Field-of-View (FOV) of a fluorescence imaging device.



FIG. 12—these timing diagrams illustrate the process of simultaneously acquiring a fluorescent image and projecting with a fluorescence imaging device.



FIG. 13—this drawing shows a method of optically combining the FOV of laser scanner and a CCD camera of a fluorescence imaging device.



FIG. 14—this drawing shows an alternative method of optically combining the FOV of laser scanner and a CCD camera of a fluorescence imaging device.



FIG. 15—this drawing shows yet another method of optically combining the FOV of laser scanner and a CCD camera of a fluorescence imaging device.



FIG. 16—this drawing shows a method of optically combining the FOV of an imaging projector, such as a DLP projector, and a CCD camera of a fluorescence imaging device.



FIG. 17—this drawing shows a fluorescence imaging device with a head-mount sensor for correcting the re-projected image.



FIG. 18—this diagram illustrates the visual enhancement of re-projected image through synchronized blinking.



FIG. 19—these timing diagrams illustrate time-resolved fluorescence detection.



FIG. 20—these timing diagrams illustrate and alternative method of lime-resolved fluorescence detection using a single-photon counter.



FIG. 21—this drawing illustrates the optical collection area trade-off between imaging and non-imaging detectors.



FIG. 22—this drawing shows multiple detectors with independent collection areas covering the same FOV.





DETAILED DESCRIPTION OF THE INVENTION


FIG. 1 shows a block diagram of a fluorescence imaging device capable of re-projecting fluorescence image directly on the human body, for example, during a surgery. A florescent dye, such as HER2Sense or RediJect 2-DG 750, which is available from Perkin Elmer in Waltham, Mass. (see, Perkin Elmer, Targeted Fluorescent Imaging Agents, available at: www.perkinelmer.com/catalog/category/id/Targeted), is delivered to the surgical area, via sub-cutaneous or intra-venous injection and accumulates in the objects of interest, for example cancer cells 11 of the patient.


A near IR laser 1 is provided at an IR frequency that is suitable for exciting the florescent dye in the cancer cells 11 of the surgical area. The near IR laser 1 passes through an alignment mechanism 3 which co axially aligns the near IR laser 1 with a visible laser 2. As a specific illustrative example, the near IR laser 1 could be a semiconductor laser diode which emits at 780 nm wavelength and the visible laser 2 can be a red laser that emits at a 640 nm wavelength. The co-axially aligned lasers beams are then delivered to a scanning mechanism 5 which moves them in a raster pattern along a field of view 9 aimed upon the surgical area 7.


When the near IR laser passes over the cancer cells 11 the florescent dye contained therein is energized and emits light in a band roughly centered around an 820 nm wavelength. The emitted light travels along detection path 10 to a filter lens 6. The filter lens 6 has optical characteristics that allow the 820 nm wavelength light traveling along detection path 10 to pass through the filter lens 6, and is focused by the filter lens 6 onto photodetector 4. The filter lens 6 also has optical characteristics that block the 780 nm near IR laser light from passing through to the photodetector 4. The photodetector 4 converts the 820 nm light emitting from the cancer cells 11 into an analog signal which is then provided processing unit 12.


In one embodiment, called the real-time mode, the processing unit 12 drives in real time a laser drive 13, which in turn turns on and off the visible laser 2 so that the visible laser 2 represents the amount of the 820 nm wavelength light falling upon the photodetector 4. In this manner, the visible laser 2 is transmitted onto the surgical area 7 thereby illuminating with visible light the locations where the fluorescent dye is present.


In another embodiment, called an image capture mode, the processing unit 12 stores a time sequence output of the photodetector 4 into a memory location. In this manner, an entire image frame representing the 820 nm fluorescence in the field of view 9 is stored in the memory location. Image processing can be performed on the memory location to enhance and augment the captured image. The processing unit 12 then outputs a time sequence output to the laser drive 13 such that the visible laser outputs the entire frame stored in the memory location. In this matter, the frame captured in the memory location is transmitted onto the surgical area thereby illuminating the visible light at the locations where the fluorescent dye is present. In this image capture mode, the output frame from the visible laser 2 is delayed in time from the image frame stored by the processing unit 12. The device of FIG. 1 can be contained in handheld devices or can be mounted on a stand. In the handheld device, provided the frame rate is adequately fast, for example, 60-100 frames per second, this delay will not result in noticeable jitter.


A further embodiment of the device of FIG. 1 is shown in FIG. 2. The elements 1-13 function in the image capture mode as described in reference to FIG. 1. Further, the processing unit 12 communicates the frame image stored in the memory representative of the 820 nm fluorescence in the field of view 9 through communications 14 circuitry to either a monitor 15 or storage 16 device, or to both the monitor 15 and the storage 16 device. The monitor 15 displays tire frame image of the fluorescence in the field of view 9. Further, the storage 16 device, such as, for example, a hard drive, solid state memory device or computer, can store the frame image and later recall the image for viewing on the monitor 15 or for archiving the frame images.


The user of the FIG. 2 embodiment will have the ability to view a visual image of the 820 nm fluorescence in the field of view 9 generated by tire visible laser 2 and scanned by the scanning mechanism 5 directly on the surgical area 7. Surgical area 7 often has a three-dimensional geometry, and the visible image is displayed on all portions of the three-dimensional geometry of the surgical area facing the direction of the scanning mechanism. Further, the user can view the visual image of the 820 nm fluorescence in the field of view 9 directly on the monitor 15. The display on the monitor can be digitally amplified or reduced to fit the user's needs.


Another embodiment of the present invention is shown on FIG. 3. All the elements are the same as FIG. 2; however, a CCD Camera 20 has been electrically connected to the processing unit 12. While the invention of FIG. 2 is operating, the CCD camera 20 takes a color image of the surgical field 7. Accordingly, the CCD camera captures an image of the surgical field 7 while the visible laser 2 is projecting a visible representation of where the florescent material is. In this manner, the CCD camera 20 captures and communicates to the processing unit 12 an image representation of both the color image of the surgical field 7 together with the projected representation of the fluorescence. Such combined image can then be displayed on the monitor. In order to display just the visible image, without the fluorescence the near IR laser can be temporarily turned off thereby stopping the fluorescing and thereby the CCD camera images just the visible image.


The projected visible image captured by camera can also be analyzed by the processing unit in order to provide the most accurate alignment of the projected image on curved surfaces of the body with the captured fluorescent image.


A further embodiment of the present invention is shown in FIG. 4 wherein a color representation of the surgical area 7 is captured together with the fluorescent representation of the surgical area 7.


Within a surgical field a surgical area is treated with a florescent dye, the florescent dye accumulates in, for example, the cancer cells 11 of the patient. The florescent dye can be injected into the blood stream of the patient or can be locally injected near the suspect cancer cells 11.


A near IR laser 1 is provided at an IR frequency that is suitable for exciting the florescent dye in the cancer cells 11 of the surgical area. The near IR laser 1 passes through an alignment mechanism 3 which co axially aligns the near IR laser 1 with a green laser 2A, a blue laser 2B and a red laser 2C. As an specific illustrative example, the near IR laser 1 could be a semiconductor laser diode which emits at 780 nm wavelength, the visible red laser 2C can be a 640 nm semiconductor red laser, the visible blue laser 2B can be a 440 nm semiconductor blue laser, and the visible green laser 2A can be a can be a laser emitting in the a 510 to 540 nm range. The co-axially aligned lasers are then provided to a scanning mechanism 5 which move the coaxially aligned laser beams in a raster pattern along a field of view 9 aimed upon the surgical area 7.


When the near IR laser passes over the cancer cells 11 in the surgical area 7, the florescent dye contained therein is energized and emits light in a band roughly centered around an 820 nm wavelength. The emitted 820 nm wavelength light travels along detection path 10 to a lens 6A. The lens 6A has optical characteristics to focus the 820 nm wavelength light traveling along detection path 10 onto photodetector IR 4D. A 820 nm pass filter 17D is provided which allows the 820 nm wavelength to pass while rejecting visible light reflected off the surgical area 7 from the red laser 2C, the green laser 2A and the blue laser 2B laser as well as rejecting the Near IR light from reflecting off the surgical area from the near IR laser 1. The 820 nm pass filter 17D is positioned between the lens 6A and the Photodetector IR 4D. In this manner the photodetector IR 4D receives only the 820 nm fluorescent emission from the surgical area 7 and converts the 820 nm light emitting within the surgical area 7 into an analog signal which is then provided processing unit 12. The processing unit 12 converts the analog signal from photodetector IR 4d into a digital signal which is stored on a frame by frame basis in 820 nm frame memory 18d


When the green laser 2A, blue laser 2B and Red laser 2C passes over the surgical area 7 within the field of view 9, the visible color characteristics of the surgical area 7 are reflected to varying degrees depending upon the visible color of the surgical area 7. The reflected light travels along detection path 10 to a lens 6A. The lens 6A has optical characteristics to focus the reflected green laser 2A, blue laser 2B and red laser 20 light traveling along detection path 10 onto each of photodetectors 4A-4C, respectively. A green pass filter 17A, a blue pass filter 17B and a red pass filter 17C, which allows only their respective colors of visible light to pass through, are positioned between the lens 6A and the respective photodetectors 4A-4C. In this manner each of the respective photodetectors 4A-4C receives only one of the three reflected colors, and each photodetector 4A-4C converts the respective light into analog signals which are then provided to processing unit 12. The processing unit 12 converts the analog signal from the respective photodetectors 4a-4c into a digital signal which is stored on a frame by frame basis in green frame memory 18a, blue frame memory 18b and red frame memory 18c, respectively.


In this manner, an entire frame representing the 820 nm fluorescence in the field of view 9 together with a color image of the surgical area 7 within the field of view 9 is stored within frame memory 18a-18d of the processing unit 12. To directly illuminate the areas within the surgical area 7 that emitted the 820 nm light, the 820 nm frame memory 18d is mapped to a selected color for projection onto the surgical area 7. For example, if a red color is selected as the display color, the processing unit 12 outputs a time sequence of the frame within the 820 nm frame memory to the red laser drive 13c such that the red laser 2c is driven to output, onto the surgical area the image stored within the 820 nm frame memory. Accordingly, the surgeon will see directly on the surgical area 7 the red laser projection at the locations where the 820 nm fluorescence occurred. While in the present embodiment, the red laser 2C was utilized for projecting the visible image onto the surgical area 7, in alternative embodiments, any desired combination of the red laser 13c, the blue laser 13b and the green laser 13A could be used to project a desired visible color.


In the present embodiment, the image contained in the 820 nm frame buffer can mapped to a visible color and superimposed onto one or more of the green, blue or red frame memories 18a-18c and the resulting modified frame memories 18a-18c are then displayed on monitor 15 and output to storage 16. For example, in an embodiment wherein bright green is selected as the color for displaying on the monitor 15 the image of the fluorescence stored in 820 nm frame memory 18d, then green frame memory 18a is modified based upon the contents of 820 nm frame memory 18d, such that bright green is stored in green frame memory 18a at the locations where the 820 nm frame memory 18d stored indication of florescence detection.


Accordingly, with the present invention the surgeon has two ways of viewing fluorescence within the surgical area 7. In the first, the visible lasers (one or more of the green, blue and red lasers 18a-18c are projected directly on the surgical site and directly locations which are fluorescing. Further, the image of the fluorescing is mapped to a color and display on the monitor 15 together with a color image of the surgical area 7.


In this embodiment, the color lasers 2A-2C are used to illuminate the surgical area 7 to capture a color image, and one or more of the color lasers is used to project the representation of the areas of fluorescence. This can be accomplished by time multiplexing the lasers 2A-2C. For example, every other frame can be allocated for the capture of the color image and the alternate flames can be allocated to displaying via the one or more color lasers 2a-2c the representation of the fluorescence. The net effect will be a white background with the image of the florescence superimposed thereon.


There exists a large number of fluorophores which can be utilized with the present invention. Each fluorophores is activated by particular frequency of light, and emits a particular frequency of light. It is understood that the Near IR laser 1 can be of any frequency sufficient to activate the emissions of the fluorophore, and the 820 nm pass filler 17d and the photodetector IR 4d, can be modified to allow the frequency of light emitted by the fluorophore to be passed and detected. In this manner the present invention is applicable for the wide array of fluorophores. In a still further embodiment, it is possible to utilize two or more fluorophores, having different optical characteristics, at the same time with the surgical area 7. The device of FIG. 4 can be modified so that there are additional lasers incorporated for activating the fluorophores, and additional pass filters and photodetectors for detecting the different frequencies of light, emitted by the fluorophores. Controls can be incorporated to select which lasers should be activated based upon the fluorophores utilized in a procedure. Further, an auto select mode can be implemented where each laser for exciting the fluorophores is momentarily turned on, and only if a reflection is received from the corresponding fluorophores is that channel used in the steady state operation of the device.



FIG. 5 is the same as FIG. 4 with the addition of an ablation laser 21. In an embodiment wherein the florescent dye is introduced to bind to cancer cells 11, in addition to causing the visible light to illuminate cancer cells 11, an ablation laser 21 can be controlled so that it turns on only when the lasers are aimed by the scanning mechanism at the cancer cells.


In an alternative embodiment, the scanning mechanism can particularly be a pointing mirror (as opposed to a resonance mirror). In this manner, the ablation laser 21 can be aimed at the desired cancer location for a prolonged period of time to enable sufficient heating to destroy the cells.


Early success with laser ablation on various types of cancer patients has been achieved at the Mayo Clinic (see, “Mayo Clinic Finds Early Success with Laser That Destroys Tumors with Heat.” available at: http://www.mayoclinic.org/news2010-jax/6006.html). The device of FIG. 5 can be used to more particularly control the aiming of the laser so that it falls only on the desired locations.



FIG. 6 is an embodiment wherein a projector (which can be of any type, for example, loser projector, DLP projector, LCD projector, is configured solely for projecting visible light of one or more colors. An IR light source, at a frequency sufficient to cause a fluorophore to emit a different frequency of light, is aimed at the surgical site. The IR light source can either flood the surgical site or can be a scanned light source. A camera is configured to detect a wide frequency range of light, including the visible spectrum and the frequency emitted by the fluorophore. The captured image is stored in a processing unit wherein it is then displayed on a monitor and also could be stored in storage for record keeping. Further the portion of the captured image corresponding to the frequency emitted by the fluorophore. In this case 820 nm, is provided to the projector which in turn projects the image onto the surgical area. Accordingly, a surgeon can see the florescence by either viewing the monitor or directly looking at the surgical area.


Embodiments presented on FIGS. 1 . . . 6 are further illustrated with a simplified layout of FIG. 7. Light collection system 103 insures that the light emitted by fluorophore particles reaches the light detectors 108. Filters 4 are chosen to correspond to the emission bandwidth of fluorophores 105. Detectors 108 convert light into electrical signals which are processed in electronic block 109, which forms a 2D image corresponding to the distribution of fluorophores in tissue. Said image is presented on the monitor 110.


Some of the detectors 108 and filters 104 may be configured to receive the reflected light from excitation lasers 101 or projection lasers 111 (of which more below), in addition to fluorescence light. That enables the device to act like a camera in IR and/or visible bands. Electronic block 109 may also perform various image-enhancing processing steps, such as integration over multiple frames, contrast enhancing, etc.


In addition to color mapping, the electronic block 109 is also responsible for brightness mapping of certain levels of light emitted by fluorophores to corresponding levels of power of the projection lasers. Such mapping could be linear, single binary threshold, etc. Additionally, the electronic block 109 may produce other video effects to emphasize certain features of the image, such as blinking or periodic color changes.


In is also possible to modulate the brightness of the illumination lasers in accordance with the distribution of light collected from the fluorophore. Applying more illumination where fluorescence is weak and less illumination where it is strong would increase the effective dynamic range of acquired image.


Since the light emitted by fluorophores is usually scant, the corresponding electrical signals are week and susceptible to noise. To optimize image quality, the electronic block may be performing on-the-fly noise estimates and adjust the brightness mapping accordingly. Additionally, the electronic block may tune the bandwidth of the signal processing tract depending on the minimal feature size in the observed fluorescent image.


In clinical practice, it is often important to overlap the image representing fluorescent signature of the tissue with a regular image of the same area. To achieve that, an imaging camera 112 can be employed, looking at the same field of view as the scanner. The camera will pick up both the reflected colors of the tissue and the image re-projected by the projection lasers. Preferably, colors distinct from tissue colors should be chosen for re-projection. It is also beneficial to synchronize the frame rate of the camera with that of the scanner.


Detectors 108 are typically photo-diodes (PD), with appropriate electronic gain down the signal tract. However, in order to improve signal-to-noise (SNR) ratio and facilitate detection of very weak signals, a photo-multiplier tube (PMT) may be used.


Also, to improve fluorescent light collection, a non-imaging light collection system can be used, since non-imaging light collectors can be substantially larger than imaging ones. The difference between them is illustrated on FIG. 8. The imaging collection system 115 has the ability to collect light from a point A or B on the target into a point A′ or B′ on the detector. A non-imaging system 116 can only collect light from a point on the target into a relatively large area (AA′ or BB′) on the detector, making it unsuitable for use with pixelated sensors. In a scanning device, however, only temporal resolution of the detector matters. Refractive, diffractive or reflective non-imaging collectors may be used.


The use of very large collectors in conjunction with PMT or other high-sensitivity detectors enables imagine of internal tissues, where the scanned raster of the excitation and projection light is delivered through the endoscope 113 (FIG. 9), while the fluorescent light is collected externally, coming through skin 117. A miniature endoscopic camera 114 may still be used to produce a combined image with fluorescent features superimposed over regular optical image. A miniature endoscopic camera in and of itself is typically incapable of picking up weak fluorescent light.


Additional advantage of scanning fluorescence detector is its ability to resolve signals in time domain, thus distinguishing between fast- and slow-decaying fluorophores, even if their emission spectra are identical. FIG. 10 shows an excitation laser beam 118 scanning across fluorophore particle 105 and the temporal graphs of excitation light 119 and responses of fast (120) and slow (121) fluorophores. To increase time resolution, the excitation laser itself may be modulated and the temporal response detected synchronously, possibly, with integration across several frames.


It was also disclosed that coupling such a scanning detection device with an imaging camera may be particularly advantageous, as the fluorescent image from the scanner may be superimposed upon the color image from the camera to provide geometrically-accurate, clinically-relevant information not otherwise visible to the surgeon.


To realize full benefits of such alignment, it is important to establish the correspondence between data captured by the scanning device 201 and imaging camera 203, (FIG. 11). This is facilitated by projecting a frame 2 around the field of view (FOV) of the scanning device 1, or some other registration elements which are fixed in the FOV, such as corners. For best results, the frame rate of the camera should be synchronized with that of the scanner, via camera's trigger input or other arrangement. Assuming that the attire scanning FOV is contained within the camera FOV 4, the position of such registration elements can be detected by the camera and their coordinates within the camera FOV can be established. Then the coordinates of ail other pixels of the scanning device can be found within the camera FOV by interpolation.


If the target surface is not planar, the registration elements may nor be able to convey all the information needed for alignment every pixel of both scanner's and camera's images. In this case the entire projected image may be analyzed and used for alignment.


However, inclusion of the projected registration elements, as well as detected fluorescent structures 5, may degrade the quality of the camera image. To avoid that, a camera can capture frames with variable timing and the image processing software may process frames in two streams, as depicted on FIG. 12. In this case “bright” frames 226 are captured while projection frames 223 are active and used for alignment only, while “dark” frames 225 are captured while projection frames 223 are not active and used for fusion with bio-fluorescence data. The exposure of “bright” and “dark” frames may be different. Additionally, partial “bright” frames may be captured during a single camera exposure and subsequently stitched in software. This would have an advantage of capturing more “dark” frames and hence providing fused frames with clinically-relevant information at higher rate, while “bright” frames captured at lower rate may still provide sufficient alignment precision.


Additionally, still referring to FIG. 12, non-active projection periods 224, during which all lasers of the scanning device are off, can be used to capture so-called “black” frames from the scanning device, i.e. frames which contains no fluorescence data, just noise. The data in those frames may be filtered or otherwise processed, stored, and then subtracted from frames with valid data. While thermal noise and some other forms of noise are non-repeatable and hence cannot be canceled out this way, the ambient light noise and the electronic interference from internal and external sources may me repeatable and hence may be reduced or eliminated by black frame subtraction.


The electronic alignment by registration elements as described above may need considerable processing resources. In some cases it may be advantageous to align the scanning device and a camera opto-mechanically, in such a way that their optical axes are co-located along the same line 6 what reaching the target surface 8 (FIG. 13). To achieve this, a coaxial coupling element 207 is employed. Such coupling element may be a dichroic mirror (if the wavelengths used by the scanning device and the camera are sufficiently different), or a polarizing mirror or polarizing cube (if the light used by the scanning device is linearly polarized and the camera can tolerate the loss of half the light), or even a half-mirror (if both the scanning device and the camera can tolerate the loss of some light). Other configurations of the coupling element are possible too.


If a coaxial coupling element is not feasible, a small coupling mirror 227 placed right outside of the camera FOV may be employed to bring the FOVs of the scanning device and the camera to nearly-coaxial direction (FIG. 14). In this case, some electronic alignment may still be necessary, however, the computational intensity and the precision of such alignment are greatly improved.


If mirror 227 is significantly smaller than the camera's aperture, it may be employed within the camera FOV, as per FIG. 15. In this case, it blocks some of the aperture, but the amount of light entering the camera around it may still be sufficient.


It may also be advantageous to employ an additional objective 211, which would create a virtual image of the origin point of the scanner somewhere near the mirror 227, thus reducing the required size of the mirror 227. Similar optical arrangement with an additional objective may be used for the camera as well.


No matter which arrangement is used for the coupling, it is advantageous to co-locate the origin points of the scanning device and the camera, so the relative size of their FOVs stay's constant or nearly constant, irrespective of the distance to the target.


While a laser scanning device is capable of re-projecting the collected bio-luminescent information onto the target, it may be advantageous to use a different, non-scanning projector for this purpose. The advantages of non-scanning projectors may include higher light output and lower cost. It is conceivable to use a powerful DLP or LCoS-based non-scanning projector as a replacement of a surgical light, so the projected image will not have to compete with ambient light.


As with cameras, for best results, the frame rate of a projector should be synchronized with that of the scanner.


All of the above-mentioned alignment methods can be used for an imaging projector as well. This is illustrated by an example on FIG. 16, where two coupling mirrors 27a and 27b are placed within the FOV of a projector 10 (most imaging projectors have fairly large apertures). Additional objectives 211a and 211b insure the smallest possible size of coupling mirrors, and hence, low loss of projector's light. A parabolic hot mirror 209 is also shown, collecting the fluorescent light into a detector 212. This arrangement assumes that the fluorescent light has longer wavelength than visible light (emitted by the projector and captured by the camera). Generally, a detector 212 may be collocated with the scanner 201, or be positioned in a different place, as the position of the detector has little impact on device's sensitivity.


The projected light may hit the target surface in such a way that an abnormally large (FIG. 17) or abnormally small amount of light will be reflected toward the User's eyes, due to specular reflection. This problem may be alleviated by a sensor wearable by the User near his/her eyes, which would provide feedback for the projector controller, and thus adjust the amount of light going to each particular pixel of the image according to surface reflectance at that point in the direction of the User.


The visibility of the projected pattern 214 (FIG. 18), indicating detected fluorescence, may be enhanced, if it is divided into two or more sub-areas, which blink in a synchronized fashion. Left part of FIG. 18 shows a magnified projected pattern 214, which is on the right, where 215 and 216 represent two such sub-areas, designated by different hatching: for example, when areas 215 are lit up, areas 216 remain dark, and vice versa. Areas might be one pixel each, or larger.


A unique property of a scanning bio-fluorescence detection device is its ability to provide time-resolved data. To take advantage of it, the excitation laser should emit pulses 217, their duration being considerably shorter than the duration of a scanning pixel (FIG. 19). The detection system should also be fast enough to be able to take multiple read-outs 219 within a scanning pixel. Then, a temporal response 218 can be measured. This temporal data can be used to assess the fluorophore temporal response, as in Fluorescence-Lifetime Imaging Microscopy (FLIM), or to assess the time of light propagation from the fluorescence source, and hence, the depth of such source, enabling tomographic imaging.


For time-resolved measurements, it is especially advantageous to use a single-photon counting detector. Then, instead of continuous response curve 218 as on FIG. 10, a number of pulses 220 would be detected, as depicted on FIG. 20. Statistical analysis of their time of arrival can provide the most accurate information about fluorescence-lifetime and/or the depth of fluorescent sources in the body.


It may also be possible to use multiple excitation lasers emitting short pulses within the same pixels and using the same detector to read multiple fluorophores. In this case, preferably, the fluorophores should have fairly short life time.


Additionally, the reflected light from one or more excitation lasers can be detected and co-processed with fluorescent light, thus enhancing the collected image.


It is hence advantageous to use fast, highly sensitive detectors, such as Avalanche Photo-Diode (APD), Silicon Photo-Multiplier (SiPM), Photo-Multiplier Tube (PMT) Hybrid Photo-Multiplier (HPM) or other, characterized by short response time, high gain and low noise. It is also advantageous to use detectors with large active area, as those may collect more photons. Additionally, the size of optical collection area 222 may grow proportionally to the active area of the detector 221, so that

  • where d is the size of the optical collection area, S is the size of the active area of the detector. A is the size of the target, and h is the distance from the device to the target, as per FIG. 21.


Additionally, it may also be advantageous to employ multiple detectors 221a . . . 221e, each with its own optical collection area 222a . . . 222c, looking at the same target area (FIG. 22).


After both fluorescent image and color image are captured and aligned, various image fusion methods can be employed.


It may be particularly advantageous to capture the image formed by reflected excitation light in addition to the fluorescent image. The reflected image is usually providing more detailed, higher resolution information about the location of the fluorescent inclusions, while also being perfectly aligned with fluorescent image. The image data from the camera can then be used to colorize the reflected image, which otherwise is black-and-white.


It may also be advantageous to co-process the fluorescent and reflected image, for example, normalizing the fluorescent data by reflected data.


Also, additional information may be extracted from the analysis of temporal changes of the fluorescent images such as the direction and velocity of the blood flow, the pulse or other physiological factors. The contrast and quality of the fluorescent image can also be improved by storing the image taken before the fluorophore has been injected and comparing it with the image after the fluorophore injection.

Claims
  • 1. A method for three-dimensional imaging of cancer cells of a target surgical area comprising: introducing fluorophores having affinity for binding to targeted cancer cells into biologic tissues of internal body structures of the target surgical area;emitting a beam of light from a first laser at an infrared wavelength and a beam light from a second laser at a visible wavelength within each of a respective first and second plurality of alternating imaging frames, said infrared wavelength selected for causing excitation of the fluorophores and emission of a fluorescent excitation wavelength of light by the excited fluorophores;co-axially aligning said emitted beams of infrared light and visible light using a means for aligning;scanning said co-axially aligned beam of light, using a means for scanning, in a two dimensional pattern, spanning across the target surgical area, exciting the fluorophores and causing emitting of the fluorescent excitation light at a second infrared wavelength during each of the first plurality of alternating imaging frames;receiving, by a detector, each of said first plurality of alternating image frames;converting into an analog signal, by the detector, each image of the fluorescent excitation light of the fluorophores for each of the first plurality of alternating imaging frames;transmitting each analog signal output by the detector to a processing unit;converting the analog signal of each fluorophore image into a digital image by the image processor, and successively storing each in a memory;creating black frames succeeding each set of the first and second plurality of alternating image frames by shutting off the first and second lasers for capturing only ambient noise using the detector;subtracting the captured noise of each black frame from the digital fluorophore image of a previous one of said first alternating image frames using the image processor;andsuccessively outputting each noise-subtracted digital fluorophore image to the second laser as an analog signal, by the image processor, and illuminating the fluorophores of the target surgical area with visible light from the second laser during each of the second alternating imaging frames using the analog signal of the noise-subtracted fluorophore image.
  • 2. The method according to claim 1 further comprising: configuring a camera for simultaneously capturing an image of both visible wavelengths of light and the fluorescent excitation wavelength of light;using the camera for capturing an image of the target surgical area and the fluorophores; anddisplaying the captured image of the target surgical area and the fluorophores on a display monitor.
  • 3. The method according to claim 2 further comprising storing said captured image of the target surgical area and the fluorophores for record keeping.
  • 4. The method according to claim 1 further comprising: selectively emitting light from a third laser at a cancer cell ablation wavelength usable for ablating cancer cells;co-axially aligning said selectively emitted light from the third laser with said co-axially aligned beam of light from said first laser and second laser, using the means for aligning, for scanning of said selectively emitted ablation wavelength of light in the pattern, using the means for scanning; andusing the signal, by said processing unit, for causing said selectively emitting of light by the second laser at said cancer cell ablation wavelength for only occurring when directed at a position in said scanning corresponding to the received excitation wavelength of light from the fluorophores in the image, for ablating of the targeted cancer cells.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 14/097,313, filed on Dec. 5, 2013, which claims priority on U.S. Provisional Application Ser. No. 61/733,535 filed on Dec. 5, 2012, and which also claims priority on U.S. Provisional Application Ser. No. 61/830,225, filed on Jun. 3, 2013, all disclosures of which are incorporated herein by reference.

US Referenced Citations (295)
Number Name Date Kind
3136310 Meltzer Jan 1960 A
3349762 Kapany Oct 1967 A
3511227 Johnson May 1970 A
3527932 Thomas Sep 1970 A
3818129 Yamamoto Jun 1974 A
3984629 Gorog Oct 1976 A
4030209 Dreiding Jun 1977 A
4057784 Tafoya Nov 1977 A
4109647 Stern et al. Aug 1978 A
4162405 Chance et al. Jul 1979 A
4182322 Miller Jan 1980 A
4185808 Donohoe et al. Jan 1980 A
4213678 Pomerantzeff et al. Jul 1980 A
4265227 Ruge May 1981 A
4312357 Andersson et al. Jan 1982 A
4315318 Kato et al. Feb 1982 A
4321930 Jobsis et al. Mar 1982 A
4393366 Hill Jul 1983 A
4495949 Stoller Jan 1985 A
4502075 DeForest et al. Feb 1985 A
4510938 Jobsis et al. Apr 1985 A
4536790 Kruger et al. Aug 1985 A
4565968 Macovski Jan 1986 A
4567896 Barnea et al. Feb 1986 A
4576175 Epstein Mar 1986 A
4590948 Nilsson Mar 1986 A
4586190 Tsuji Apr 1986 A
4587972 Morantte May 1986 A
4596254 Adrian et al. Jun 1986 A
4619249 Landry Oct 1986 A
4669467 Willett et al. Jun 1987 A
4672963 Barken Jun 1987 A
4697147 Moran et al. Sep 1987 A
4699149 Rice Oct 1987 A
4703758 Omura Nov 1987 A
4766299 Tierney et al. Aug 1988 A
4771308 Tejima et al. Sep 1988 A
4780919 Harrison Nov 1988 A
4785806 Deckelbaum Nov 1988 A
4799103 Muckerheide Jan 1989 A
4817622 Pennypacker et al. Apr 1989 A
4846183 Martin Jul 1989 A
4861973 Hellekson et al. Aug 1989 A
4862894 Fujii Sep 1989 A
4887605 Angelsen Dec 1989 A
4899756 Sonek Feb 1990 A
4901019 Wedeen Feb 1990 A
4926867 Kanda et al. May 1990 A
RE33234 Landry Jun 1990 E
4932412 Goldenberg Jun 1990 A
4938205 Nudelman Jul 1990 A
5010886 Passafaro Apr 1991 A
5074642 Hicks Dec 1991 A
5088493 Giannini et al. Feb 1992 A
5103497 Hicks Apr 1992 A
5146923 Dhawan Sep 1992 A
5174298 Dolfi et al. Dec 1992 A
5184188 Bull et al. Feb 1993 A
5214458 Kanai May 1993 A
5222495 Clarke et al. Jun 1993 A
5261581 Harden, Sr. Nov 1993 A
5293873 Fang Mar 1994 A
5339817 Nilsson Aug 1994 A
5371347 Plesko Dec 1994 A
5406070 Edgar et al. Apr 1995 A
5418546 Nakagakiuchi et al. May 1995 A
5423091 Lange Jun 1995 A
5424841 Van Gelder Jun 1995 A
5436655 Hiyama et al. Jul 1995 A
5445157 Adachi et al. Aug 1995 A
D362910 Creaghan Oct 1995 S
5485530 Lakowicz et al. Jan 1996 A
5487740 Sulek et al. Jan 1996 A
5494032 Robinson et al. Feb 1996 A
5497769 Gratton et al. Mar 1996 A
5504316 Bridgelall et al. Apr 1996 A
5519208 Esparza et al. May 1996 A
5541820 McLaughlin Jul 1996 A
5542421 Erdman Aug 1996 A
5588432 Crowley Dec 1996 A
5598842 Ishihara et al. Feb 1997 A
5603328 Zucker et al. Feb 1997 A
5608210 Esparza et al. Mar 1997 A
5608520 Fleming Mar 1997 A
5610387 Bard et al. Mar 1997 A
5625458 Alfano et al. Apr 1997 A
5631976 Bolle et al. May 1997 A
5655530 Messerschmidt Aug 1997 A
5678555 O'Connell Oct 1997 A
5716796 Bull et al. Feb 1998 A
5719399 Alfano et al. Feb 1998 A
5735275 Ballou et al. Apr 1998 A
5740801 Branson Apr 1998 A
5747789 Godik May 1998 A
5756981 Roustaei et al. May 1998 A
5758650 Miller et al. Jun 1998 A
5772593 Hakamata Jun 1998 A
5787185 Clayden Jul 1998 A
5814040 Nelson et al. Sep 1998 A
5836877 Zavislan Nov 1998 A
5847394 Alfano et al. Dec 1998 A
5860967 Zavislan et al. Jan 1999 A
5929443 Alfano et al. Jul 1999 A
5946220 Lemelson Aug 1999 A
5947906 Dawson, Jr. et al. Sep 1999 A
5966204 Abe Oct 1999 A
5966230 Swartz et al. Oct 1999 A
5969754 Zeman Oct 1999 A
5982553 Bloom et al. Nov 1999 A
5988817 Mizushima et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995866 Lemelson Nov 1999 A
6006126 Cosman Dec 1999 A
6032070 Flock et al. Feb 2000 A
6056692 Schwartz May 2000 A
6061583 Ishihara et al. May 2000 A
6083486 Weissleder et al. Jul 2000 A
6101036 Bloom Aug 2000 A
6113536 Aboul-Hosn et al. Sep 2000 A
6122042 Wunderman et al. Sep 2000 A
6132379 Patacsil et al. Oct 2000 A
6135599 Fang Oct 2000 A
6141985 Cluzeau et al. Nov 2000 A
6142650 Brown et al. Nov 2000 A
6149061 Massieu et al. Nov 2000 A
6149644 Xie Nov 2000 A
6171301 Nelson et al. Jan 2001 B1
6178340 Svetliza Jan 2001 B1
6230046 Crane et al. May 2001 B1
6240309 Yamashita et al. May 2001 B1
6251073 Imran et al. Jun 2001 B1
6263227 Boggett et al. Jul 2001 B1
6272376 Marcu et al. Aug 2001 B1
6301375 Choi Oct 2001 B1
6305804 Rice et al. Oct 2001 B1
6314311 Williams et al. Nov 2001 B1
6334850 Amano et al. Jan 2002 B1
6353753 Flock et al. Mar 2002 B1
6424858 Williams Jul 2002 B1
6436655 Bull et al. Aug 2002 B1
6438396 Cook et al. Aug 2002 B1
6463309 Ilia Oct 2002 B1
6464646 Shalom et al. Oct 2002 B1
6523955 Eberl et al. Feb 2003 B1
6542246 Toida Apr 2003 B1
6556854 Sato et al. Apr 2003 B1
6556858 Zeman Apr 2003 B1
6599247 Stetten Jul 2003 B1
6631286 Pfeiffer et al. Oct 2003 B2
6648227 Swartz et al. Nov 2003 B2
6650916 Cook et al. Nov 2003 B2
6689075 West Feb 2004 B2
6690964 Bieger et al. Feb 2004 B2
6702749 Paladini et al. Mar 2004 B2
6719257 Greene et al. Apr 2004 B1
6755789 Stringer et al. Jun 2004 B2
6777199 Bull et al. Aug 2004 B2
6782161 Barolet et al. Aug 2004 B2
RE38670 Asah Dec 2004 E
6845190 Smithwick et al. Jan 2005 B1
6882875 Crowley Apr 2005 B1
6889075 Marchitto et al. May 2005 B2
6913202 Tsikos et al. Jul 2005 B2
6923762 Creaghan, Jr. Aug 2005 B1
6980852 Jersey-Willuhn et al. Dec 2005 B2
7092087 Kumar et al. Aug 2006 B2
7113817 Winchester, Jr. et al. Sep 2006 B1
7158660 Gee, Jr. et al. Jan 2007 B2
7158859 Wang et al. Jan 2007 B2
7204424 Yavid et al. Apr 2007 B2
7225005 Kaufman et al. May 2007 B2
7227611 Hull et al. Jun 2007 B2
7239909 Zeman Jul 2007 B2
7247832 Webb Jul 2007 B2
7280860 Ikeda et al. Oct 2007 B2
7283181 Allen et al. Oct 2007 B2
7302174 Tan et al. Nov 2007 B2
7333213 Kempe Feb 2008 B2
D566283 Brafford et al. Apr 2008 S
7359531 Endoh et al. Apr 2008 B2
7376456 Marshik-Geurts et al. May 2008 B2
7428997 Wiklof et al. Sep 2008 B2
7431695 Creaghan Oct 2008 B1
7448995 Wiklof et al. Nov 2008 B2
7532746 Marcotte et al. May 2009 B2
7545837 Oka Jun 2009 B2
7559895 Stetten et al. Jul 2009 B2
7579592 Kaushal Aug 2009 B2
7608057 Woehr et al. Oct 2009 B2
7699776 Walker et al. Apr 2010 B2
7708695 Akkermans et al. May 2010 B2
7792334 Cohen et al. Sep 2010 B2
7846103 Cannon, Jr. et al. Dec 2010 B2
7848103 Zhan Dec 2010 B2
7904138 Goldman et al. Mar 2011 B2
7904139 Chance Mar 2011 B2
7925332 Crane et al. Apr 2011 B2
7966051 Xie et al. Jun 2011 B2
8032205 Mullani Oct 2011 B2
8078263 Zeman et al. Dec 2011 B2
8187189 Jung et al. May 2012 B2
8199189 Kagenow et al. Jun 2012 B2
8320998 Sato Nov 2012 B2
8336839 Boccoleri et al. Dec 2012 B2
8364246 Thierman Jan 2013 B2
8467855 Yasui Jun 2013 B2
8480662 Stolen et al. Jul 2013 B2
8494616 Zeman Jul 2013 B2
8498694 McGuire, Jr. et al. Jul 2013 B2
8509495 Xu et al. Aug 2013 B2
8537203 Seibel et al. Sep 2013 B2
8548572 Crane Oct 2013 B2
8630465 Wieringa et al. Jan 2014 B2
8649848 Crane et al. Feb 2014 B2
9220917 Boyden Dec 2015 B2
20010006426 Son et al. Jul 2001 A1
20010056237 Cane et al. Dec 2001 A1
20020016533 Marchitto et al. Feb 2002 A1
20020118338 Kohayakawa Aug 2002 A1
20020188203 Smith et al. Dec 2002 A1
20030018271 Kimble Jan 2003 A1
20030052105 Nagano et al. Mar 2003 A1
20030120154 Sauer et al. Jun 2003 A1
20030125629 Ustuner Jul 2003 A1
20030156260 Putilin et al. Aug 2003 A1
20040015062 Ntziachristos et al. Jan 2004 A1
20040015158 Chen et al. Jan 2004 A1
20040022421 Endoh et al. Feb 2004 A1
20040046031 Knowles et al. Mar 2004 A1
20040171923 Kalafut et al. Sep 2004 A1
20040222301 Willins et al. Nov 2004 A1
20040237051 Clauson Nov 2004 A1
20050017924 Utt et al. Jan 2005 A1
20050033145 Graham et al. Feb 2005 A1
20050043596 Chance Feb 2005 A1
20050047134 Mueller et al. Mar 2005 A1
20050085732 Sevick-Muraca et al. Apr 2005 A1
20050085802 Gruzdev et al. Apr 2005 A1
20050113650 Pacione et al. May 2005 A1
20050131291 Floyd et al. Jun 2005 A1
20050135102 Gardiner et al. Jun 2005 A1
20050141069 Wood et al. Jun 2005 A1
20050143662 Marchitto et al. Jun 2005 A1
20050146765 Turner et al. Jul 2005 A1
20050154303 Walker et al. Jul 2005 A1
20050157939 Arsenault et al. Jul 2005 A1
20050161051 Pankratov et al. Jul 2005 A1
20050168980 Dryden et al. Aug 2005 A1
20050174777 Cooper et al. Aug 2005 A1
20050175048 Stern et al. Aug 2005 A1
20050187477 Serov et al. Aug 2005 A1
20050215875 Khou Sep 2005 A1
20050265586 Rowe et al. Dec 2005 A1
20050281445 Marcotte et al. Dec 2005 A1
20060007134 Ting Jan 2006 A1
20060020212 Xu et al. Jan 2006 A1
20060025679 Viswanathan et al. Feb 2006 A1
20060052690 Sirohey et al. Mar 2006 A1
20060081252 Wood Apr 2006 A1
20060100523 Ogle et al. May 2006 A1
20060103811 May et al. May 2006 A1
20060122515 Zeman et al. Jun 2006 A1
20060129037 Kaufman et al. Jun 2006 A1
20060129038 Zelenchuk et al. Jun 2006 A1
20060151449 Warner, Jr. et al. Jul 2006 A1
20060173351 Marcotte et al. Aug 2006 A1
20060184040 Keller et al. Aug 2006 A1
20060206027 Malone Sep 2006 A1
20060232660 Nakajima et al. Oct 2006 A1
20060253010 Brady et al. Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20060276712 Stothers Dec 2006 A1
20070015980 Numada et al. Jan 2007 A1
20070016079 Freeman et al. Jan 2007 A1
20070070302 Govorkov et al. Mar 2007 A1
20070115435 Rosendaal May 2007 A1
20070176851 Willey et al. Aug 2007 A1
20070238957 Yared Oct 2007 A1
20080045841 Wood et al. Feb 2008 A1
20080147147 Griffiths et al. Jun 2008 A1
20080194930 Harris et al. Aug 2008 A1
20080214940 Benaron Sep 2008 A1
20090018414 Toofan Jan 2009 A1
20090082629 Dotan Mar 2009 A1
20090171205 Kharin et al. Jul 2009 A1
20100051808 Zeman et al. Mar 2010 A1
20100061598 Seo Mar 2010 A1
20100087787 Woehr et al. Apr 2010 A1
20100177184 Berryhil et al. Jul 2010 A1
20100312120 Meier Dec 2010 A1
20110275932 Leblond et al. Nov 2011 A1
20130147916 Bennett et al. Jun 2013 A1
20140039309 Harris et al. Feb 2014 A1
20140046291 Harris et al. Feb 2014 A1
20140194747 Kruglick Jul 2014 A1
Foreign Referenced Citations (22)
Number Date Country
2289149 May 1976 FR
1298707 Dec 1972 GB
1507329 Apr 1978 GB
S60-108043 Jun 1985 JP
04-042944 Feb 1992 JP
07-255847 Oct 1995 JP
08-023501 Jan 1996 JP
08-164123 Jun 1996 JP
2000-316866 Nov 2000 JP
2002-328428 Nov 2002 JP
2002-345953 Dec 2002 JP
2004-237051 Aug 2004 JP
2004-329786 Nov 2004 JP
2003-0020152 Mar 2003 KR
WO 1994 22370 Oct 1994 WO
WO 1996 39925 Dec 1996 WO
WO 1998 26583 Jun 1998 WO
WO 1999 48420 Sep 1999 WO
WO 2001-827826 Nov 2001 WO
WO 2003-009750 Feb 2003 WO
WO 2005-053773 Jun 2005 WO
WO 2007-078447 Jul 2007 WO
Non-Patent Literature Citations (9)
Entry
Wiklof, Chris, “Display Technology Spawns Laser Camera,” LaserFocusWorld, Dec. 1, 2004, vol. 40, Issue 12, PennWell Corp., USA.
Nikbin, Darius, “IPMS Targets Colour Laser Projectors,” Optics & Laser Europe, March 1006, Isue 137, p. 11.
http://sciencegeekgirl.wordpress.com/category/science-myths/page/2/ Myth 7: Blood is Blue.
http://www.expioratorium.edu/sports/hnds_up/hands6.html “Hands up! To Do & Notice: Getting the Feel of Your Hand”.
http://www.wikihow.com/See-Blook-Veins-in-Your-Hand-Wth-a- Flashlight “How to See Blood Veins in Your Hand With a Flashlight”.
He, X., Wang, K. & Cheng, Z., “In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes,” Wire's Nanomedicine & Nanobiotechnology, Aug. 2010, vol. 2, John Wiley & Sons, Inc.
Thermo Scientific, Fluorescent Probes, available at: www.piercenet.com/browse.cfm?fldID+4DD9D52E-5056-8A76-4E6E-E217FAD0D86B.
Perkin, Elmer, “Targeted Fluorescent Imaging Agents,” available at: www.perkinelmer.com/catalog/category/id/Targeted.
“Mayo Clinic Finds Early Success with laser that Destroys Tumors with Heat,” available at: www.mayoclinic.org/news2010-jax/6006.html.
Related Publications (1)
Number Date Country
20200100681 A1 Apr 2020 US
Provisional Applications (2)
Number Date Country
61830225 Jun 2013 US
61733535 Dec 2012 US
Continuations (1)
Number Date Country
Parent 14097313 Dec 2013 US
Child 16701363 US